Participated · Equity · Oct 2025

Canara Robeco AMC Ltd. operates as an asset management company formed by Canara Bank and ORIX Corporation Europe NV. In preparation for its stock-market debut, the firm is conducting an initial public offering that is entirely an Offer for Sale, meaning the company itself will not receive any IPO proceeds. The IPO price band has been set at ₹253–266 per share, and retail investors can bid in lots of 56 shares (minimum outlay of ₹14,896). Prior to the IPO opening, the company allotted 1.49 million shares to anchor investors at the top-end price of ₹266. This anchor placement raised ₹397 million from more than 15 institutional investors. The IPO aims to sell shares worth ₹1,326 million, giving Canara Robeco AMC a post-issue market capitalisation of about ₹5,305 million. Trading in the shares is scheduled to commence on 16 October after the subscription closes and allotment is finalised.

Participated · Series C · Apr 2025

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.

Participated · Equity · Nov 2021

SATLANTIS builds multispectral infrared satellite technology to capture and measure greenhouse gas emissions, notably high-precision methane detection. The company is developing a GEI-SAT satellite for Enagás and offers satellite-based monitoring services via microsatellite systems. SATLANTIS has completed six space missions and claims world-leading optical space observation technology. A US subsidiary exists to support growth in the North American market and the company plans to develop new products and services for that market. The latest financing round brought new international investment to accelerate emissions-monitoring services and support the energy transition. Sean O'Keefe was appointed President of SATLANTIS LLC as part of the company’s U.S. leadership and partnership effort. Satlantis develops extreme miniaturisation camera technology and environmental satellites for Earth observation, with projects endorsed by Copernicus and the European Space Agency. The company led the OPTISSE project for European Defence, heading a six‑company consortium and demonstrating feasibility of 50cm resolution with its miniaturised cameras. It is building a new environmental satellite covering the visible, shortwave and mid‑wave infrared spectrum to detect methane emissions. That methane‑detection satellite is scheduled for launch in June 2023 and aligns with upcoming European regulation on methane for the Oil & Gas sector. Satlantis plans to use recent financing to pursue internationalisation to the US, the UK, Central Asia and the United Arab Emirates and to shorten industry lead times by offering satellite solutions in months rather than years. The company also received a rating of excellence from the European Commission, which awarded a follow‑on project to focus OPTISSE results on maritime monitoring. Satlantis develops satellite sensors and solutions focused on environmental monitoring, including methane detection, marine plastic identification and fire detection. The company says its methane measurement capability reaches very high precision (5 meters), a resolution it describes as previously unattained. Leadership includes Jean‑Jacques Dordain, former director general of the European Space Agency. Satlantis employs about 45 engineers and positions itself to serve customers across the value chain, including Copernicus, ESA missions and the oil & gas sector. With the new funding the company plans to launch SATLANTIS International to develop activity in the USA, UK and the United Arab Emirates. Satlantis develops high-resolution imaging cameras that integrate into nanosatellites to capture real-time images of the Earth’s surface. The company was founded in 2014 and counts former minister Cristina Garmendia among its founders. Satlantis is focused on qualifying its cameras for space launch and standardizing devices to enable series manufacturing. It operates in the industrial automation/robotics sector with R&D and manufacturing plans centered in Bilbao, Basque Country. In March 2016 the company closed a €2.35M venture-capital round intended to support product development and a new factory in Bilbao. The round involved strategic and institutional investors collaborating to back the company’s next development phase.

Participated · Series C · Apr 2016

Founded in 2010 and based in Barcelona, STAT-Dx develops the DiagCORE in vitro diagnostic system, a cartridge-based single-test platform that consolidates molecular and immunoassay techniques. DiagCORE is designed to identify a wide range of infectious pathogens (meningitis, respiratory, gastro-intestinal) and deliver results in roughly one hour to support faster clinical decisions in ICUs and emergency rooms. The company aims to replace complex diagnostic protocols with a near-to-care solution that tests simultaneously for multiple pathogens associated with syndrome panels. STAT-Dx planned CE-marking for a respiratory panel application by the end of 2017 and is pursuing commercialisation and clinical validation. The business is backed by a strong shareholder base of leading international healthcare investors and has sought institutional financing to bridge early market introduction to wider commercial roll-out. The EIB loan described in the articles is intended to accelerate development, commercialisation and market introduction of the DiagCORE platform. STAT-Diagnostica develops near-patient testing solutions and is the maker of the DiagCORE integrated molecular and immunoassay diagnostics system. DiagCORE performs all on-board sample preparation for a wide range of sample types and offers up to 48-multiplex capability via real-time PCR, with time-to-results of roughly 30–80 minutes depending on the assay. The system is designed for true walk-away diagnostics and aims to deliver lab-like performance with high usability. STAT-Diagnostica plans to target decentralized testing environments including critical care and emergency units, clinics, and physician offices, and the system has CLIA-waivable features for broader use. The company intends to use the financing to prepare for a 2017 European launch of DiagCORE. STAT-Diagnostica was founded in 2010 in Barcelona and is led by CEO and co-founder Jordi Carrera. STAT-Diagnostica builds a versatile in vitro Near Patient Testing platform that consolidates molecular and immunoassay techniques in a single, easy-to-use device. The system offers multi-analyte and multi-sample capabilities and delivers results in less than 30 minutes. Initial clinical applications target infectious disease detection, antibiotic resistance determination, and biomarkers in critically ill patients. The company plans to use the Series B proceeds to complete development of its diagnostic system and to finish clinical validation of its first products. STAT-Diagnostica was founded in 2010 and is based in the Barcelona Science Park. Management has stated the financing will support preparation for a European market launch in 2015. STAT Diagnostica develops point-of-care in-vitro diagnostic solutions for clinical applications. Its platform is designed to perform both molecular diagnostics and immunoassays. The company intends its main applications to address infectious diseases, antibiotic resistance detection and measurement of biomarkers in critical or urgent care patients. STAT Diagnostica is based at Barcelona Science Park and was founded in 2010. Managing Director Jordi Carrera leads the company. It recently raised €2m in Series A financing to advance development of its point-of-care diagnostics platform.

Participated · Equity · Oct 2013

Volotea is a low-cost airline operating across European routes and carried 11.2 million passengers in 2025. The carrier reported strong operational metrics in 2025, with a 79% on-time performance rate and a 99.7% flight completion rate. Financially, Volotea completed a capital raise that brought in €71 million in March 2026 after an investment process that began in September 2024. Investors in the transaction include Aegean Airlines, which increased its stake, PAR Capital, and Alaeo representing management. The airline plans to use the new capital to expand its network, enhance operational efficiency, grow its fleet, and invest in greener technologies and sustainable aviation fuel options. These measures are intended to support Volotea’s sustainable growth and competitive position in the European low-cost travel market.